Genprex, Inc.
Gene therapies for cancer and diabetes using proprietary viral vectors and genetic modification
- Sector
- Biotech
- Headquarters
- Austin, TX
- Founded
- 2009
- Latest Form D
- $1.5M offered, Nov 2019
- Total capital
- $13.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $13.1M
- 7 Form D · last Nov 2019
- 83 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 14 pending
Capital timeline
Latest events
- Offering registeredForm D · SEC · 7th filing$1.5M
- Private capital raisedForm D · SEC · 6th filing$10M
- Private capital raisedForm D · SEC · 5th filing$950K
- Private capital raisedForm D · SEC · 4th filing$160K
- Private capital raisedForm D · SEC · 3rd filing$100K
- Private capital raisedForm D · SEC · 2nd filing$1.4M
- Private capital raisedForm D · SEC · 1st filing$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Bob PearsonDirectorNamed in SEC Form D filings
- David Rodney FriedmanDirectorNamed in SEC Form D filings
- John Rodney VarnerExecutive Officer, DirectorNamed in SEC Form D filings
- Julien M. PhamExecutive OfficerNamed in SEC Form D filings
- Robert W. PearsonDirectorNamed in SEC Form D filings
- Ryan Rodney ConferExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 14- PendingVectors for Increasing NPRL2 Expression in Cancer Cells and Methods of Use ThereofUSPTOApplication 18710542
- PendingMethods And Compositions For Treating GlioblastomaUSPTOApplication PCTUS2025044601
- PendingMaintenance Therapy For Treating CancerUSPTOApplication PCTUS2025022360
Show all 14 patent records
- Vectors for Increasing NPRL2 Expression in Cancer Cells and Methods of Use ThereofJan 2, 2025 · Application 18710542Pending
- Methods And Compositions For Treating GlioblastomaApplication PCTUS2025044601Pending
- Maintenance Therapy For Treating CancerApplication PCTUS2025022360Pending
- Methods Of Treating Pet Positive CancersApplication PCTUS2025015091Pending
- Treatment Of Alk Positive CancersApplication PCTUS2025014874Pending
- Treatment Of Cancer Using Combined TUSC2/TUSC4 Gene TherapyApplication PCTUS2024015417Pending
- Methods of Treating PET Positive CancersApplication 63550978Pending
- Treatment Of Cancer Using Combined TUSC2/TUSC4 Gene TherapyApplication 63484306Pending
- Vectors For Increasing NPRL2 Expression In Cancer Cells And Methods Of Use ThereofApplication PCTUS2022079978Pending
- Vectors For Increasing NPRL2 Expression In Cancer Cells And Methods Of Use ThereofApplication 63279871Pending
- Nonviral Vectors For Increasing Fas Expression In Cancer Cells And Methods Of Use ThereofApplication PCTUS2021050327Pending
- Nonviral Vectors For Increasing Fas Expression In Cancer Cells And Methods Of Use ThereofApplication 63078145Pending
- Methods And Compositions For Treating MesotheliomaApplication PCTUS2025044862Pending
- Treatment Of Cancer Using Combined TUSC2/TUSC4 Gene TherapyApplication 19149150Pending
Related companies, and why
- Carmine Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- ImmunoCellular Therapeutics, Ltd.Similar federal contract value in Biotech · null in contracts
- Morphoceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Convelo Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Octagon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- nferenceSimilar federal contract value in Biotech · null in contracts
Press
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene TherapyPRNewswire
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .